Results 171 to 180 of about 8,062,145 (231)

Treprostinil: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT Treprostinil is a synthetic prostacyclin analogue with a tricyclic benzindene structure that confers markedly enhanced metabolic stability relative to native prostacyclin, enabling delivery by four distinct routes—intravenous, subcutaneous, inhaled, and oral—that together constitute a mainstay of pharmacotherapy for pulmonary arterial ...
Muhammad Sameed, Muhammad Waleed, Veronika Colomy   +2 more
wiley   +1 more source

Completion and outcomes of postmarketing requirements and commitments issued by the US Food and Drug Administration for new drugs, 2016-24: cross sectional evaluation of postmarketing studies. [PDF]

BMJ Med
Siebert M, McGonigle R, Gutiérrez-Sacristán A, Naci H, Wagner AK, Bourgeois FT.   +5 more
europepmc   +1 more source

Balancing Innovation and Access: Insights from AIM's Fair Pricing Model and Its Current and Future Applications. [PDF]

Pharmacoeconomics
Stokx J, Hendrickx A, Veliste K, Brouns C, Scheffler S, Schoch GG, Slapsak M, Macken E, Walter P, Kanga-Tona T, Barjesteh van Waalwijk van Doorn-Khosrovani S.   +10 more
europepmc   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10318-10329, November 2026.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

What Drives Public Preference for Rare Drugs Coverage in China? Insights From a Multi-Center Discrete Choice Experiment. [PDF]

Health Expect
Wu Y, Chen J, Shao J, Peng H, Li L, Chen G, Li S.   +6 more
europepmc   +1 more source

Social Diseases and Social Problems: An Islamic Framework for Cultural Awareness And Social Diagnosis

Sociological Inquiry, Volume 96, Issue 4, 2026.
Despite decades of policy interventions, the world suffers from profound social problems including drug abuse, family breakdown, and systemic injustice. The research problem is the persistent gap in existing sociological theories: objective criteria lacking for diagnosing social harm before it becomes visible.
Jilani Ben Touhami Meftah
wiley   +1 more source

A year in pharmacology: new drugs approved by the US food and drug administration in 2025. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC.   +3 more
europepmc   +1 more source

Natural Product‐Induced Ferroptosis to Overcome Therapy Resistance in Aggressive Cancers

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
Natural products trigger ferroptosis through iron overload, glutathione depletion, glutathione peroxidase 4 inhibition, and reactive oxygen species accumulation, selectively targeting aggressive, and drug‐resistant cancers. Polyphenols, alkaloids and terpenoids emerge as promising multi‐target agents to overcome therapy resistance and improve future ...
Giorgio Antoniolli
wiley   +1 more source

Development Timelines of Innovative Drugs in China: A 15-Year Cross-Sectional Analysis of Characteristics and Influencing Factors. [PDF]

Clin Transl Sci
Xu M, Wang C, An X.
europepmc   +1 more source

A cost-based-plus pricing approach for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome. [PDF]

Orphanet J Rare Dis
Manders E, Keestra S, Bannenberg W, van der Wel V, de Visser S, Hollak C.   +5 more
europepmc   +1 more source